Skip to main content
Company profile
Adicet Bio logo

Adicet Bio

Pipeline2 assets

  • Prulacabtagene leucelprula-cel; formerly ADI-001 / CD20 / Allogeneic gamma delta CAR T cell therapy / Autoimmune diseases
    Lupus nephritisPhase 1activeSystemic lupus erythematosusPhase 1activeSystemic sclerosisPhase 1active
  • ADI-212ADI-212 / PSMA / Next-generation gene-edited and armored allogeneic CAR gamma delta T cell therapy / Oncology
    Metastatic castration-resistant prostate cancerPreclinicalactive

Latest news10 items

All news

Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

- Prula-cel shown to be generally well tolerated with no CRS greater than Grade 2 and no IEC-HS or ICANS - -At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR- -All patients discontinued immunosuppressants – - All but one patient tapered background

Trial Results • Phase 1Data announcement Mon, Sep 28, 2026, 6:45 AM EDT

Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Sep. 25, 2026-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today

Results Call • Phase 1Results call Mon, Sep 28, 2026, 8:00 AM ET

Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update

Prula-cel topline results from planned analysis expected September 2026 FDA clearance of IND for ADI-212 in mCRPC; Phase 1 clinical study expected to initiate in 4Q 2026 Unveiling next-generation in vivo CAR-T platform and pipeline targeting hematological malignancies and solid tumors; first

Trial Results • Phase 1Prula-cel planned analysis completion Tue, Sep 1, 2026, 7:00 AM EDT

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Aug. 31, 2026-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Phase 1 study in patients with mCRPC expected to begin enrollment in the fourth quarter of 2026 REDWOOD CITY, Calif. --(BUSINESS WIRE)--Aug. 27, 2026-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo

Adicet Bio • Endpoint Arena